Personal information

No personal information available

Activities

Collapse all

Works (29)

Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial

Gastroenterology
2025-02 | Journal article
DOI: 10.1053/j.gastro.2024.09.030
Contributors: Jessica R. Allegretti; Colleen R. Kelly; Thomas Louie; Monika Fischer; Susy Hota; Bharat Misra; Nick W. Van Hise; Eugene Yen; Jeffrey S. Bullock; Michael Silverman et al.
Source: check_circle
Crossref

Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the ELEVATE UC Clinical Program

2025-02-26 | Other
DOI: 10.1093/ibd/izae308
Contributors: Gary R Lichtenstein; Jessica R. Allegretti; Edward V. Loftus Jr; Peter M. Irving; Rupa Banerjee; Aline Charabaty; Tanja Kuehbacher; Eustratios Bananis; John C. Woolcott; Alexis B. Dalam et al.
Source: check_circle
Crossref

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS

Inflammatory Bowel Diseases
2025-01-25 | Journal article
DOI: 10.1093/ibd/izae291
Contributors: Jessica R Allegretti; Paul Feuerstadt; Whitfield L Knapple; Robert Orenstein; Philippe Pinton; Alexander Sheh; Sahil Khanna
Source: check_circle
Crossref

Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program

Inflammatory Bowel Diseases
2024-12-13 | Journal article
DOI: 10.1093/ibd/izae288
Contributors: Andres J Yarur; Michael V Chiorean; Jessica R Allegretti; Raymond K Cross; Christina Ha; Martina Goetsch; Aoibhinn McDonnell; Alexis B Dalam; Joseph Wu; David A Blanco et al.
Source: check_circle
Crossref

The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond

Gastroenterology
2024-10 | Journal article
DOI: 10.1053/j.gastro.2024.05.004
Contributors: Jessica R. Allegretti; Sahil Khanna; Benjamin H. Mullish; Paul Feuerstadt
Source: check_circle
Crossref

Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort

Inflammatory Bowel Diseases
2024-10-03 | Journal article
DOI: 10.1093/ibd/izad242
Contributors: Rahul S Dalal; Puza P Sharma; Kanwal Bains; Jordan C Pruce; Jessica R Allegretti
Source: check_circle
Crossref

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Inflammatory Bowel Diseases
2024-09-19 | Journal article
DOI: 10.1093/ibd/izae215
Contributors: Rahul S Dalal; Lindsay M Clarke; Alex Carlin; Heidy Cabral; Jessica R Allegretti
Source: check_circle
Crossref

1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

Inflammatory Bowel Diseases
2024-08-01 | Journal article
DOI: 10.1093/ibd/izad165
Contributors: Rahul S Dalal; Puza P Sharma; Kanwal Bains; Jordan C Pruce; Jessica R Allegretti
Source: check_circle
Crossref

Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study

Inflammatory Bowel Diseases
2024-07-03 | Journal article
DOI: 10.1093/ibd/izad155
Contributors: Rahul S Dalal; Govind Kallumkal; Heidy J Cabral; Salam Bachour; Edward L Barnes; Jessica R Allegretti
Source: check_circle
Crossref

Review article: The epidemiology and management of Clostridioides difficile infection—A clinical update

Alimentary Pharmacology & Therapeutics
2024-06 | Journal article
DOI: 10.1111/apt.17975
Contributors: Lindsay M. Clarke; Jessica R. Allegretti
Source: check_circle
Crossref

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Advances in Therapy
2024-05 | Journal article
DOI: 10.1007/s12325-024-02818-9
Contributors: Jessica R. Allegretti; Jessica H. Brady; Ann Wicker; Mark Latymer; Alvin Wells
Source: check_circle
Crossref

Challenges in IBD Research 2024: Pragmatic Clinical Research

Inflammatory Bowel Diseases
2024-05-23 | Journal article
DOI: 10.1093/ibd/izae083
Contributors: Jessica R Allegretti; Liliana G Bordeianou; Oriana M Damas; Samuel Eisenstein; Ruby Greywoode; Phillip Minar; Siddharth Singh; Sabrina Harmon; Eugene Lisansky; Myisha Malone-King et al.
Source: check_circle
Crossref

1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure

Inflammatory Bowel Diseases
2024-03-01 | Journal article
DOI: 10.1093/ibd/izad087
Contributors: Rahul S Dalal; Puza P Sharma; Kanwal Bains; Jordan C Pruce; Jessica R Allegretti
Source: check_circle
Crossref

Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?

Inflammatory Bowel Diseases
2024-03-01 | Journal article
DOI: 10.1093/ibd/izad309
Contributors: Rahul S Dalal; Jessica R Allegretti
Source: check_circle
Crossref

How Would You Manage This Patient With Clostridioides difficile Infection?

Annals of Internal Medicine
2023-08 | Journal article
DOI: 10.7326/M23-0754
Contributors: Zahir Kanjee; Jessica R. Allegretti; Carolyn D. Alonso; Risa B. Burns
Source: check_circle
Crossref

Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis

Gastroenterology
2023-08 | Journal article
DOI: 10.1053/j.gastro.2023.03.230
Contributors: Jessica R. Allegretti; Vanessa Mitsialis; James B. Canavan; Scott B. Snapper; Matthew Hamilton; Jared Barends; Madeline Carrellas; Katherine Freer; Jordan Gringauz; Julia Green et al.
Source: check_circle
Crossref

Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn’s-like Disease of the Pouch

Inflammatory Bowel Diseases
2023-06-01 | Journal article
DOI: 10.1093/ibd/izac165
Contributors: Brandon M Shore; Kimberly N Weaver; Jessica R Allegretti; Hans H Herfarth; Edward L Barnes
Source: check_circle
Crossref

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

Inflammatory Bowel Diseases
2023-05-02 | Journal article
DOI: 10.1093/ibd/izac164
Contributors: Rahul S Dalal; Jordan C Pruce; Jessica R Allegretti
Source: check_circle
Crossref

Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis

Digestive Diseases and Sciences
2023-01 | Journal article
DOI: 10.1007/s10620-022-07472-1
Contributors: Rahul S. Dalal; Emma L. McClure; Jenna Marcus; Jessica R. Allegretti
Source: check_circle
Crossref

Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply

Alimentary Pharmacology & Therapeutics
2023-01 | Journal article
DOI: 10.1111/apt.17303
Contributors: Benjamin H. Mullish; Laura Martinez‐Gili; Jessica R. Allegretti
Source: check_circle
Crossref

The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation

Therapeutic Advances in Gastroenterology
2023-01 | Journal article
DOI: 10.1177/17562848231165581
Contributors: Salam P. Bachour; Rahul Dalal; Jessica R. Allegretti
Source: check_circle
Crossref

Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series

Inflammatory Bowel Diseases
2022-11-02 | Journal article
DOI: 10.1093/ibd/izac147
Contributors: Rahul S Dalal; Kanwal Bains; Jenna Marcus; Emma L McClure; Jessica R Allegretti
Source: check_circle
Crossref

Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders

Inflammatory Bowel Diseases
2022-01-05 | Journal article
DOI: 10.1093/ibd/izab156
Contributors: Rahul S Dalal; Sanchit Gupta; Hannah Goodrick; Jennifer Mitri; Jessica R Allegretti
Source: check_circle
Crossref

Infliximab De-escalation in Patients With Crohn’s Disease in Clinical Remission Is Safe and Well-tolerated

Inflammatory Bowel Diseases
2021-11-15 | Journal article
DOI: 10.1093/ibd/izab131
Contributors: Jessica R Allegretti; Andrew Canakis; Emma McClure; Jenna Marcus; Beth-Ann Norton; Matthew J Hamilton; Rachel W Winter; Punyanganie S De Silva; Sonia Friedman; Joshua R Korzenik
Source: check_circle
Crossref

Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?

Inflammatory Bowel Diseases
2021-10-20 | Journal article
DOI: 10.1093/ibd/izab002
Contributors: Rahul S Dalal; Jessica R Allegretti
Source: check_circle
Crossref

Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis

Inflammatory Bowel Diseases
2021-10-18 | Journal article
DOI: 10.1093/ibd/izab097
Contributors: Rahul S Dalal; Jennifer Mitri; Hannah Goodrick; Jessica R Allegretti
Source: check_circle
Crossref

Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019

JGH Open
2021-05 | Journal article
DOI: 10.1002/jgh3.12497
Contributors: Jessica R Allegretti; Cheikh Nije; Emma McClure; Walker D Redd; Danny Wong; Joyce C Zhou; Ahmad N Bazarbashi; Thomas R McCarty; Kelly E Hathorn; Lin Shen et al.
Source: check_circle
Crossref

Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All

Inflammatory Bowel Diseases
2021-05-17 | Journal article
DOI: 10.1093/ibd/izab019
Contributors: Rahul S Dalal; Jessica R Allegretti
Source: check_circle
Crossref

Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases

Inflammatory Bowel Diseases
2021-03-15 | Journal article
DOI: 10.1093/ibd/izab023
Contributors: Rachel W Winter; Ashwin Ananthakrishnan; Kristin E Burke; Bharati Kochar; Walter W Chan; Jessica R Allegretti
Source: check_circle
Crossref

Peer review (7 reviews for 5 publications/grants)

Review activity for Clinical gastroenterology and hepatology (1)
Review activity for EClinicalMedicine. (1)
Review activity for Gastroenterology. (3)
Review activity for Nature (1)
Review activity for The Lancet. (1)
How many people are using ORCID?